Laurence Malbert-Colas

Laurence Malbert-Colas

Auto-generated profile, based on publicly available information

Laurence Malbert-Colas

Institut de Recherche Saint Louis, Unité Mixte de Recherches 1342, Université Paris Cité, Hôpital St. Louis

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JHJustine Habault
Justine Habault
NSNorman Salomao
Norman Salomao
LWLixiao Wang
Lixiao Wang
LMLaurence Malbert-Colas
Laurence Malbert-Colas
CDChrysoula Daskalogianni
Chrysoula Daskalogianni
Robin FahraeusRobin Fahraeus
Robin Fahraeus
The p53 tumor suppressor and the c-Myc oncogene are among the most frequently deregulated genes in human cancers, yet the molecular cross talk between these pathways remains poorly understood. MDM2 is a key negative regulator of p53 and a target for emerging cancer therapies designed to activate p53. Likewise, targeting c-Myc is a long-standing but challenging goal in cancer therapy. Here, we report that the small MDM2-binding drug Milademetan promotes an interaction between MDM2 and the 5’ untranslated region of the c-Myc mRNA, causing a suppression of c-Myc mRNA translation without affecting c-Myc RNA levels. The interaction also occurs under nonproliferative conditions in the absence of drug. Milademetan-mediated c-Myc depletion is accompanied by the induction of apoptosis and suppression of cell proliferation and prevents tumor growth, independently of p53 status. These findings reveal an unexpected mechanism by which MDM2 coordinates two of the most frequently altered pathways in cancer and provide a rationale for targeting c-Myc-driven tumors, including those lacking functional p53, through MDM2 modulators.